[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Ohishi Y, Oda Y, Uchiumi T, Kobayashi H, Hirakawa T, Miyamoto S, Kinukawa N, Nakano H, Kuwano M, Tsuneyoshi M: ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma. Clin Cancer Res; 2002 Dec;8(12):3767-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ATP-binding cassette superfamily transporter gene expression in human primary ovarian carcinoma.
  • PURPOSE: The purpose of this study is to attempt to characterize patients with unfavorable clinical outcome by the relative mRNA levels of ABC transporter expression in their tumor samples and to examine whether relative mRNA levels of each of the ABC transporters can be a useful predictor of progression-free survival in advanced ovarian carcinoma.
  • EXPERIMENTAL DESIGN: We examined tumor samples taken from 30 patients with primary serous papillary adenocarcinoma of the ovary for the expression of MDR1 and MRP1, MRP2, and MRP3 mRNA by using real-time reverse transcription-PCR, and we evaluated its correlation with clinical outcome.
  • All 30 patients were divided into three groups according to clinical outcome after debulking surgery and platinum-based chemotherapy: 8 patients were classified into the unfavorable group; 11 were classified into the favorable group; and 11 were classified into intermediate group.
  • In the 30 patients with serous papillary adenocarcinoma, univariate and multivariate analysis demonstrated that the high relative mRNA levels of MRP1 expression were significantly correlated with a short period of progression-free survival.
  • CONCLUSIONS: In patients with advanced ovarian serous papillary adenocarcinoma, these results suggest that patients with an unfavorable clinical outcome are characterized by increased levels of coordinated MRP1 and MRP3 mRNA expression in their tumor samples.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Serous / genetics. Drug Resistance, Multiple. Membrane Transport Proteins. Multidrug Resistance-Associated Proteins / genetics. Ovarian Neoplasms / genetics. RNA, Messenger / metabolism
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. DNA Primers / chemistry. Disease-Free Survival. Drug Resistance, Neoplasm. Female. Gene Expression. Humans. Immunoenzyme Techniques. Middle Aged. P-Glycoprotein / genetics. P-Glycoprotein / metabolism. Prognosis. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12473588.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / Membrane Transport Proteins; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / multidrug resistance-associated protein 1; 0 / multidrug resistance-associated protein 2; 0 / multidrug resistance-associated protein 3
  •  go-up   go-down


2. Gregory-Bass RC, Olatinwo M, Xu W, Matthews R, Stiles JK, Thomas K, Liu D, Tsang B, Thompson WE: Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis. Int J Cancer; 2008 May 1;122(9):1923-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis.
  • Current approaches to the treatment of ovarian cancer are limited because of the development of resistance to chemotherapy.
  • Prohibitin (Phb1) is a possible candidate protein that contributes to development of drug resistance, which could be targeted in neoplastic cells.
  • Phb1 is a highly conserved protein that is associated with a block in the G0/G1 phase of the cell cycle and also with cell survival.
  • Our study was designed to determine the role of Phb1 in regulating cellular growth and apoptosis in ovarian cancer cells.
  • Our results showed that Phb1 content is differentially overexpressed in papillary serous ovarian carcinoma and endometrioid ovarian adenocarcinoma when compared to normal ovarian epithelium and was inversely related to Ki67 expression.
  • Immunofluorescence microscopy and Western analyses revealed that Phb1 is primarily associated with the mitochondria in ovarian cancer cells.
  • Over-expression of Phb1 by adenoviral Phb1 infection resulted in an increase in the percentage of ovarian cancer cells accumulating at G0/G1 phase of the cell cycle.
  • Treatment of ovarian cancer cells with staurosporine (STS) induced apoptosis in a time-dependent manner.
  • In contrast, silencing of Phb1 expression by adenoviral small interfering RNA (siRNA) sensitized ovarian cancer cells to STS-induce apoptosis.
  • Furthermore, silencing of the Phb1 gene expression may prove to be a valuable therapeutic approach for chemoresistant ovarian cancer by increasing sensitivity of cancer cells to apoptosis.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] EMBO J. 2000 Jun 1;19(11):2444-51 [10835343.001]
  • [Cites] Exp Gerontol. 1996 Jan-Apr;31(1-2):245-52 [8706794.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1699-706 [11245486.001]
  • [Cites] Exp Cell Res. 2001 May 1;265(2):262-73 [11302691.001]
  • [Cites] Endocrinology. 2001 Sep;142(9):4076-85 [11517187.001]
  • [Cites] Mech Ageing Dev. 2002 Feb;123(4):287-95 [11744041.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4539-48 [12085232.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):44870-6 [12244097.001]
  • [Cites] Exp Cell Res. 2003 Feb 15;283(2):135-45 [12581734.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1496-505 [12639934.001]
  • [Cites] Cell Death Differ. 2003 Aug;10(8):870-80 [12867994.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):32091-9 [12794069.001]
  • [Cites] Oncogene. 2004 Apr 15;23(17):2996-3004 [14968116.001]
  • [Cites] EMBO J. 2004 Jun 2;23(11):2293-303 [15141164.001]
  • [Cites] Biol Reprod. 2004 Jul;71(1):282-90 [15028627.001]
  • [Cites] J Reprod Fertil. 1997 Mar;109(2):337-48 [9155744.001]
  • [Cites] Mol Endocrinol. 1999 Aug;13(8):1364-72 [10446909.001]
  • [Cites] Anat Rec. 1999 Sep 1;256(1):40-8 [10456984.001]
  • [Cites] Mol Biol Cell. 2005 Jan;16(1):248-59 [15525670.001]
  • [Cites] Trends Mol Med. 2005 Apr;11(4):192-7 [15823758.001]
  • [Cites] Nat Cell Biol. 2005 Aug;7(8):837-43 [16041367.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6325-32 [16144937.001]
  • [Cites] Curr Cancer Drug Targets. 2006 May;6(3):207-27 [16712458.001]
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):36401-10 [17008324.001]
  • [Cites] Endocrinology. 2007 Jan;148(1):206-17 [17038561.001]
  • [Cites] Oncogene. 2007 Mar 15;26(12):1757-68 [16964284.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):815-9 [17429401.001]
  • [Cites] Front Biosci. 2007;12:3628-39 [17485326.001]
  • [Cites] J Biol Chem. 2007 Jul 6;282(27):19426-41 [17493932.001]
  • [Cites] Reprod Biol Endocrinol. 2003 Oct 7;1:66 [14609433.001]
  • [Cites] Proteomics. 2004 Oct;4(10):3276-87 [15378696.001]
  • [Cites] Cell. 1986 Dec 5;47(5):767-76 [3779841.001]
  • [Cites] Trends Genet. 1993 Jan;9(1):22-6 [8434413.001]
  • [Cites] J Cell Physiol. 1993 Nov;157(2):289-95 [8227162.001]
  • [Cites] Cancer Lett. 1994 Aug 15;83(1-2):201-7 [8062216.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):37101-9 [10958795.001]
  • (PMID = 18183577.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 1 C06 RR18386; United States / NCRR NIH HHS / RR / G12 RR003034; United States / NCRR NIH HHS / RR / C06 RR018386; United States / NICHD NIH HHS / HD / R01 HD057235; United States / FIC NIH HHS / TW / R21 TW006804-02S1; United States / NCRR NIH HHS / RR / RR03034; United States / NCATS NIH HHS / TR / UL1 TR000454; United States / FIC NIH HHS / TW / R21 TW006804-01; United States / NICHD NIH HHS / HD / U54 HD041749; United States / NICHD NIH HHS / HD / U54 HD041749-01; United States / NICHD NIH HHS / HD / U54 HD41749; United States / FIC NIH HHS / TW / R21 TW006804; United States / FIC NIH HHS / TW / R21 TW006804-02
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Ki-67 Antigen; 0 / RNA, Small Interfering; 0 / Recombinant Proteins; 0 / Repressor Proteins; 0 / prohibitin; EC 3.4.22.- / Caspase 3; H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ NIHMS350695; NLM/ PMC3272361
  •  go-up   go-down


3. Todoroki T, Murata S, Nakagawa Y, Ohkohchi N, Morishita Y: A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. Int Semin Surg Oncol; 2006;3:22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report.
  • BACKGROUND: Tumor spread beyond the peritoneal cavity in cases of papillary serous adenocarcinoma of the unknown primary (CUP) is a rare late event and carries a poor prognosis.
  • CASE PRESENTATION: A 71-year-old female was referred to our hospital because of a large right inguinal tumor with biopsy evidence of carcinoma as well as an elevated serum CA125 (cancer antigen 125).
  • She underwent complete resection of the right inguinal tumor and multiple pelvic tumors, which involved the rectum, ovary and uterus.
  • Pathological examination revealed the tumors to be metastases of a papillary serous adenocarcinoma with a psammoma body of CUP.
  • On the 28th postoperative day, newly developed asymptomatic small left inguinal node metastases in the setting of a normal CA125 level were removed.
  • Four and a half years after the primary resection, the CA125 level increased again and newly developed asymptomatic metastases were found in the right deep inguinal nodes and extirpated at that time.
  • CONCLUSION: Aggressive resection surgery followed by effective adjuvant chemotherapy is necessary for surviving long time without relapse of poorly prognostic patients with metastases outside of the abdominal cavity from peritoneal papillary serous adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):16-20 [11301835.001]
  • [Cites] Jpn J Cancer Res. 2001 Jun;92(6):704-9 [11429061.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1003-10 [14997197.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):443-9 [15816609.001]
  • [Cites] DICP. 1990 Mar;24(3):289-95 [2138376.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1091-4 [2400962.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):15-21 [9210704.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • (PMID = 16930493.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574334
  •  go-up   go-down


Advertisement
4. Vaidya AP, Littell R, Krasner C, Duska LR: Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:267-72
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel.
  • Uterine papillary serous carcinoma (UPSC) is more aggressive than endometrioid endometrial cancer, as it often presents with advanced disease and follows a pattern of spread that resembles the serous carcinoma of the ovary.
  • Tumor registry search was used to identify all patients with UPSC from 1990 to 2003.
  • Charts were retrospectively evaluated from patients who had received at least three cycles of carboplatin and paclitaxel as first-line chemotherapy.
  • Only patients with histologically confirmed UPSC who were treated first line with carboplatin/paclitaxel chemotherapy were included.
  • Five patients were treated with consolidation radiotherapy following first-line chemotherapy.
  • Fourteen patients achieved a complete response following chemotherapy.
  • The results of Gynecologic Oncology Group protocol 122 suggest that patients with advanced endometrial cancer have an improved progression-free survival when treated primarily with chemotherapy rather than radiation therapy.
  • The results of our study show a high response rate to paclitaxel/carboplatin outpatient chemotherapy in a group of patients historically believed to have chemoresistant disease.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Endometrial Neoplasms / drug therapy. Registries
  • [MeSH-minor] Aged. Aged, 80 and over. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Remission Induction. Retrospective Studies. Treatment Outcome

  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515602.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Shimoya K, Kunishige I, Okuno Y, Hayashi S, Komura H, Arimoto Y, Otsuki Y: [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin]. Gan To Kagaku Ryoho; 2001 Jun;28(6):845-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of papillary adenocarcinoma of the ovary that responded favorably to irinotecan hydrochloride and cisplatin after the administration of paclitaxel and carboplatin].
  • Recently, the standard treatment for advanced ovarian cancer has changed from CP therapy (cyclophosphamide, cisplatin (CDDP)) to TJ therapy (paclitaxel (TXL), carboplatin (CBDCA)).
  • Irinotecan (CPT-11) is one of the derivatives of camptotecin and has been reported to have a high efficacy for ovarian cancer.
  • In one case of ovarian cancer, chemotherapy was applied with CBDCA and TXL.
  • However, after 2 months of six courses of the chemotherapy, CA-125 was elevated.
  • The elevation of tumor marker levels in serum without the recurrent focus forced us to treat the patient with CPT-11 and CDDP for the second line chemotherapy.
  • Tumor marker levels improved at the beginning of the therapy.
  • In conclusion, CPT-11 and CDDP was effective against the recurrence of ovarian cancer treated with TJ therapy.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Camptothecin / administration & dosage. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Ovarian Neoplasms / drug therapy. Paclitaxel / administration & dosage
  • [MeSH-minor] Biomarkers, Tumor / blood. Cyclophosphamide / administration & dosage. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11432356.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Biomarkers, Tumor; 7673326042 / irinotecan; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin; CP protocol
  •  go-up   go-down


6. Fujiwara K, Maehata K, Kohno I, Yoden E, Imajo Y, Mikami Y: [A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy]. Gan To Kagaku Ryoho; 2000 Dec;27(14):2259-62
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of clear cell carcinoma of the ovary responding to a paclitaxel-carboplatin combination chemotherapy].
  • Clear cell carcinoma of the ovary is believed to be chemoresistant; therefore, choosing anticancer agents is often difficult.
  • In this report we present a case of ovarian clear cell carcinoma that showed a significant response to a combination chemotherapy with paclitaxel and carboplatin.
  • The patient is a 51-year-old Japanese female with a history of Gn-RH treatment for endometriosis that was terminated three years before the presentation of this disease.
  • The initial surgery revealed the tumor was a clear cell carcinoma of the left ovary, showing a predominantly solid growth pattern as well as papillary and tubular patterns.
  • Therefore, the tumor was considered to be grade 2.
  • Combination chemotherapy using paclitaxel at 175 mg/m2 in 3 hr intravenous infusion followed by intraperitoneal infusion of carboplatin at AUC of 7.5 as a bolus was administered.
  • We believe that the combination of paclitaxel and carboplatin is one treatment choice for clear cell carcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Middle Aged. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11142173.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and immunohistochemistry in 168 fresh-frozen biopsies and paraffin-embedded tissues.
  • In addition, Ep-CAM surface expression was evaluated by flow cytometry in several freshly established ovarian carcinoma cell lines derived from patients harboring tumors resistant to chemotherapy in vivo as well as in vitro.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • Finally, a high surface expression of Ep-CAM was found in 100% (5/5) of the chemotherapy-resistant ovarian carcinoma cell lines studied by flow cytometry.
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • The lack of Ep-CAM expression on the chelomic epithelium in the peritoneal cavity, combined with the recent development of fully human monoclonal antibodies against this surface molecule, suggest Ep-CAM as a promising target for antibody-mediated therapies in ovarian carcinoma patients harboring tumors refractory to standard treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


8. O'Toole SA, Sheppard BL, McGuinness E, Gleeson NC, Bonnar J: Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy. Int J Gynecol Cancer; 2001 Sep-Oct;11(5):365-71
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinomas of the ovary display heterogeneity in their response to chemotherapy.
  • The response of ovarian serous papillary adenocarcinomas to various cytotoxic drugs was examined using the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) (MTS) cytotoxicity assay.
  • The MTS chemosensitivity assay was performed on each tumor to examine the response to cisplatin, paclitaxel, hycamtin and the combination of cisplatin and paclitaxel.
  • Ovarian adenocarcinomas of similar stage and grade displayed varying responses to the same drug.
  • A lower concentration of the drug was often as effective as the peak plasma concentration.
  • For some specimens combination therapy was more effective for inhibiting tumor growth, and for others single-agent therapy gave a better response.
  • A chemosensitivity/resistance profile is recommended before deciding on appropriate chemotherapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cystadenocarcinoma, Serous / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Cisplatin / pharmacology. Drug Therapy, Combination. Female. Humans. Neoplasm Staging. Paclitaxel / pharmacology. Topotecan / pharmacology. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11737467.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Chang TC, Jain S, Ng KK, Hsueh S, Tsai CS, Chen HL, Chang CN: Cerebellar metastasis from papillary serous adenocarcinoma of the ovary mimicking Ménière's disease. A case report. J Reprod Med; 2001 Mar;46(3):267-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebellar metastasis from papillary serous adenocarcinoma of the ovary mimicking Ménière's disease. A case report.
  • BACKGROUND: In rare cases, cerebellar metastasis originating in serous papillary adenocarcinoma of the ovary can mimick Ménière's disease.
  • CASE: A 51-year-old woman, with complete remission after optimal maximal debulking and chemotherapy for an International Federation of Gynecology and Obstetrics IIIc primary ovarian carcinoma, presented with nausea, vomiting, vertigo and headache 18 months after surgery.
  • Histology showed a metastatic tumor consistent with the primary ovarian carcinoma.
  • CONCLUSION: In an atypical presentation in patients with metastatic ovarian carcinoma, thorough investigations should be done to rule out or confirm brain metastasis, which can be aggressively managed to prevent serious consequences and improve outcome.
  • [MeSH-major] Adenocarcinoma, Papillary / secondary. Cerebellar Neoplasms / secondary. Meniere Disease / diagnosis. Ovarian Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Middle Aged. Remission Induction

  • MedlinePlus Health Information. consumer health - Meniere's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11304872.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Vaughn DJ, Rizzo TA, Malkowicz SB: Chemosensitivity of malignant ovarian-type surface epithelial tumor of testis. Urology; 2005 Sep;66(3):658
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity of malignant ovarian-type surface epithelial tumor of testis.
  • Malignant ovarian-type surface epithelial tumors of the testis and paratestis are rare neoplasms.
  • We report a patient with metastatic disease with demonstrated responsiveness to chemotherapy treatments used in advanced ovarian cancer.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Paclitaxel / therapeutic use. Testicular Neoplasms / drug therapy. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Male. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16140110.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Amanti C, Lombardi A, Moscaroli A, Catracchia V, Lo Russo M, Marino G, Conte S, Provenza G: [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case]. G Chir; 2006 Jan-Feb;27(1-2):45-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Peritoneal papillary serous carcinoma in a patient with previous surgery for breast cancer: clinical case].
  • The peritoneal papillary serous carcinoma (PPSC) is a rare tumor more frequently revealed in female.
  • It implicate peritoneum, ovary's surface and pelvis.
  • The histology of this disease is similar to papillary serous carcinoma ovary (PSCO).
  • The cytoreductive surgery and the cisplatinum chemotherapy, and other treatments like immunotherapy and radiotherapy, increase the PSCP patient survival.
  • [MeSH-major] Breast Neoplasms / surgery. Cystadenocarcinoma, Papillary / surgery. Peritoneal Neoplasms / surgery

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608633.001).
  • [ISSN] 0391-9005
  • [Journal-full-title] Il Giornale di chirurgia
  • [ISO-abbreviation] G Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


12. Laurent I, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P: Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern. Ann Surg Oncol; 2008 Dec;15(12):3561-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results after conservative treatment of serous borderline tumors of the ovary with a micropapillary pattern.
  • OBJECTIVE: The aim of this study was to assess the outcomes of patients treated conservatively for a serous borderline ovarian tumor with micropapillary patterns (SBOT-MP).
  • METHODS: Retrospective study collecting cases of conservative treatment of SBOT-MP.
  • Eight patients underwent a unilateral salpingo-oophorectomy with a contralateral cystectomy, three a unilateral salpingo-oophorectomy, two a cystectomy, and two a bilateral cystectomy.
  • Four patients had stromal microinvasion associated with MP at histological examination of the ovarian tumor.
  • One patient received adjuvant chemotherapy.
  • RESULTS: After a median interval of 63 months (range, 18-120 months), 11 recurrences were observed: six of them exclusively on the ovary, three exclusively on the peritoneum (invasive peritoneal disease in one), and two on the ovary and peritoneum.
  • CONCLUSION: This study demonstrates that spontaneous pregnancies can be achieved after conservative treatment of SBOT-MP.
  • Nevertheless, as 2/3 of patients had bilateral ovarian involvement at the time of initial management, the recurrence rate is high.
  • However, making definitive conclusions about the safety of conservative surgery is limited by the small sample size.
  • [MeSH-major] Cystadenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Neoplasm Invasiveness. Neoplasm Staging. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18820973.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Takano M, Yoshikawa T, Kato M, Aida S, Goto T, Furuya K, Kikuchi Y: Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol; 2009;30(5):575-8
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma.
  • Clear cell carcinoma (CCC) is mostly derived from the ovary and often associated with endometriosis.
  • Case 2, a 66-year-old woman, presented with massive ascites and abdominal tumor.
  • Adjuvant chemotherapy using irinotecan and cisplatin was effective in one case.
  • The cases and a review of the literature suggested that residual tumor volume size determines the survival of these patients, and that the tumors show resistance to conventional platinum-based chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2010;31(1):4. Yoshokawa, T [corrected to Yoshikawa, T]
  • (PMID = 19899421.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 15
  •  go-up   go-down


14. Pusiol T, Zorzi MG, Morichetti D, Piscioli I, Scialpi M: Peritoneal Malignant Psammomatous Mesothelioma. World J Oncol; 2010 Aug;1(4):179-181

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psammoma bodies (PBs) are observed most commonly in papillary thyroid carcinoma, meningioma, and papillary serous cystadenocarcinoma of the ovary.
  • Contrast enhanced computed tomography showed fluid diffuse in peritoneal recesses, thick septa with micronodules in the greater omentum and adjacent enhancement of the thickened peritoneum.
  • The peritoneal biopsy revealed a superficial papillary growth of malignant epithelial-like cells with diffuse involvement of submesothelial tissues.
  • The patient was treated with chemotherapy (gemcitabine, vinorelbine, cisplatin).
  • PBs may represent an active biologic process ultimately leading to degeneration/death of tumor cells and retardation of growth of the neoplasm.
  • It may also serve as a barrier against the spread of tumor.
  • The behavior of serous psammocarcinoma is more closely similar to borderline serous tumor than to serous carcinoma.
  • Further studies are necessary to establish if massive deposition of PBs may define a new variant of psammomatous malignant mesothelioma with a favorable impact to the prognosis of usual psammomatous malignant mesothelioma, as well as in serous psammocarcinoma of the peritoneum.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Hum Pathol. 2005 Apr;36(4):372-80 [15891998.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):292-6 [2295052.001]
  • [Cites] Histopathology. 2006 Feb;48(3):223-32 [16430468.001]
  • [Cites] Arch Gynecol Obstet. 2009 Jun;279(6):931-6 [18982336.001]
  • [Cites] Acta Med Port. 2002 Sep-Oct;15(5):383-6 [12645223.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Diagn Cytopathol. 2009 Jul;37(7):534-41 [19373908.001]
  • (PMID = 29147203.001).
  • [ISSN] 1920-454X
  • [Journal-full-title] World journal of oncology
  • [ISO-abbreviation] World J Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Malignant mesothelioma / Psammoma bodies / Psammomatous malignant mesothelioma
  •  go-up   go-down


15. Figueroa P Sr, Castro Hernández C, Santibáñez Andrade M, Díaz Romero M, Morales Vázquez F, Gallardo Rincón D, Herrera Montalvo LA: Association between Mad1 G558A and ERCC1 C8092A polymorphisms and response to induction chemotherapy in advanced ovarian carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5568

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between Mad1 G558A and ERCC1 C8092A polymorphisms and response to induction chemotherapy in advanced ovarian carcinoma.
  • : 5568 Background: Platinum and taxane remain active drugs in the treatment of ovarian cancer.The polymorphism C8092A of ERCC1 is involved in NER pathway of platinum induced damage DNA and Mad1 G558A with modulation of the chromosomal segregation.
  • As primary aim we evaluated the influence of these polymorphisms in the chemotherapy response.
  • METHODS: ERCC1 C8092A and Mad1 G558A polymorphism allelic and genotypic frequency was determined on DNA isolated from blood tumor samples by PCR and specific digestion in 56 patients with cancer of advanced ovary who received induction chemotherapy with 3 courses of paclitaxel 175 mg/m<sup>2</sup> and AUC6 carboplatin every 3 weeks.
  • RESULTS: Between January 2008 to June 2008, 56 women were evaluated, with age media was 53 years, majority characteristics were stages III (66.9%) 37 and IV (33.1%) 19 patients, histology serous papillary (94.6%) high-grade differenced (73.2%).
  • Allele A for Mad1 is more frequently observed in patients with ovarian carcinoma versus in mexican healthy women (61% vs. 49%) and suggests the possibility that the polymorphism of Mad1 is a marker of risk for ovary cancer (RR = 1, 15, p < 0, 05).
  • Additionally we evaluated the predictive value of Ca 125 return to normal range after 3 chemotherapy courses, showed in 22 patients (39.28%) in univariate analysis we noted that allele G of Mad1 has been linked to improved response (p = 0.041).
  • CONCLUSIONS: This is the first study in ovary cancer that evaluates predictive value of two SNP, one of them involved in the spindle checkpoint and the other in DNA repair mechanism (NER), suggesting to Mad1 G558A likely risk polymorphism for ovary cancer and response to chemotherapy based on taxanes, which may be a predictive biomarker.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962556.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lou HM, Lou HK, Wu MJ: [Synchronous primary cancer of the endometrium and ovary]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):617-20
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancer of the endometrium and ovary].
  • To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary.
  • Methods with synchronous primary cancer of the endometrium and ovary were retrospectively reviewed .
  • Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary.
  • Synchronous primary cancer of the endometrium and ovary was difficult to be dignosed preoperatively.
  • All ovarian tumors were small with an average diameter of 7 cm.
  • endometrioid carcinomas was the main pathologic type (66.7%).
  • All patients were treated surgically followed by chemotherapy with a 3-year survival rate of 66.7% (8/12).
  • CONCLUSION: Synchronous primary endometrium and ovary cancer is a specific kind of tumor different from either the primary endometrium carcinoma or ovary carcinoma, and usually can be detected in early stage with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  •  go-up   go-down


17. Wu M, Shen K, Lang J, Huang R, Huang H, Pan L: [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma]. Zhonghua Fu Chan Ke Za Zhi; 2002 Dec;37(12):733-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transitional cell carcinoma of the ovary: one kind of uncommon type of ovarian epithelial carcinoma].
  • OBJECTIVE: To evaluated clinico-biologic behavior, prognosis and relative prognostic factors of transitional cell carcinoma of the ovary.
  • METHODS: The clinical records of 58 patients with transitional cell carcinoma of the ovary, who received treatment in the department of Obstetrics and Gynecology, Peking Union Medical College Hospital in 20 years, were reviewed retrospectively.
  • 31% of them had bilateral ovary involvement, and the median level of CA(125) was (687 +/- 365) U/L.
  • Different courses of chemotherapy were given to all patients.
  • The Cox hazards regression model was used to analyze the possible prognostic factors and revealed that tumor residuals (P < 0.01), preoperative level of CA(125) (P < 0.01), bilateral ovary involvement (P < 0.05) and lymph node metastasis (P < 0.05) were the most important prognostic factors.
  • CONCLUSIONS: Transitional cell carcinoma of ovary is an uncommon type of ovarian cancer.
  • It usually behaves better prognosis when compared with papillary serous cystadenocarcinoma of the ovary.
  • [MeSH-major] Carcinoma, Transitional Cell / mortality. Ovarian Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622917.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


18. Qian J, Shi Y, Chen X: [Clinical analysis of 25 cases of malignant transformation of endometriosis of the ovary]. Zhonghua Fu Chan Ke Za Zhi; 2000 Nov;35(11):667-9
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 25 cases of malignant transformation of endometriosis of the ovary].
  • OBJECTIVE: To study clinicopathologic characteristics, treatment and prognostic factors of malignant transformation of endometriosis of the ovary.
  • METHODS: From 1981 to 1999, a total of 25 patients with malignant transformation of endometriosis of the ovary were retrospectively analyzed.
  • Histological type: of the 25 cases, 14 were endometrioid carcinomas, 2 were clear-cell carcinomas, 2 were adenoacanthoma, 1 was serous papillary adenocarcinomas, 6 were mixed epithelium tumor of ovary.
  • Radical tumor resection combined with chemotherapy is the main therapeutic approach for malignant transformation of endometriosis of the ovary.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Endometriosis / pathology. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11218895.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Veroni S, Terzopoulou K, Anagnostopoulou I, Vassilakaki T, Grammatoglou X, Rammou R: Extraovarian peritoneal serous papillary carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):879-84

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraovarian peritoneal serous papillary carcinoma: a case report.
  • BACKGROUND: Extraovarian peritoneal serous papillary carcinoma (EPSPC) is a rare cancer closely related to ovarian carcinoma and characterized by abdominal carcinomatosis without an identifiable abdominal primary tumor.
  • CONCLUSION: The combination of cytology, histology, immunohistochemistry and clinical data is a reliable method for the preoperative diagnosis of EPSPC, allowing prompt chemotherapy as surgery may not be indicated in most cases.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovary / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Proteins / metabolism. Vacuoles / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053561.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


20. Ryu DR, Yoo TH, Kim YT, Jeong HJ, Cho NH, Kang SW: Minimal change disease in a patient with ovarian papillary serous carcinoma. Gynecol Oncol; 2004 May;93(2):554-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal change disease in a patient with ovarian papillary serous carcinoma.
  • BACKGROUND: Nephrotic syndrome (NS) is rarely associated with ovarian tumor.
  • Only five cases of NS with pathologic diagnosis have been reported in patients with ovarian tumors.
  • However, the association between minimal change disease (MCD) and ovarian tumor has not been previously reported.
  • Radiologic studies revealed a 10 x 10 x 11 cm-sized mass and multiple enlarged lymph nodes, suggesting a malignant ovarian tumor.
  • Histopathology of the mass and the kidney revealed papillary serous carcinoma of the ovary and MCD, respectively.
  • Oral prednisolone and adjuvant chemotherapy resulted in remission of NS.
  • CONCLUSION: We herein report a case of MCD associated with ovarian carcinoma.
  • [MeSH-major] Cystadenocarcinoma, Papillary / complications. Cystadenocarcinoma, Serous / complications. Nephrosis, Lipoid / complications. Ovarian Neoplasms / complications

  • Genetic Alliance. consumer health - Minimal change disease.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15099980.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Möbus VJ, Gerharz CD, Weikel W, Merk O, Dreher L, Kreienberg R, Moll R: Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation. Gynecol Oncol; 2001 Dec;83(3):523-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of a human carcinosarcoma cell line of the ovary established after in vivo change of histologic differentiation.
  • Most ovarian cancer cell lines described are serous cystadenocarcinomas or poorly differentiated adenocarcinomas.
  • The establishment of ovarian cancer cell lines with rare histologic differentiation is especially of interest.
  • We describe the establishment of a carcinosarcoma cell line of the ovary after in vivo selection.
  • METHODS: The cell line OV-MZ-22 was established from a solid tumor mass in the upper abdomen.
  • At the time of establishment, the patient underwent secondary debulking and was pretreated with six cycles of cis-platinum/epirubicin/cyclophosphamide.
  • RESULTS: The first histologic report of the patient described a papillary cystadenocarcinoma, which changed to a carcinosarcoma with predominantly sarcomatous differentiation at secondary debulking.
  • This cell line is aneuploid and shows no expression of the tumor-associated antigens CA-125 and CEA, but an overexpression of MDR-1, lung resistance protein, p53, and topoisomerase I and II, but not of multidrug-resistance-associated protein.
  • The histologic and immunocytochemical comparison of the primary and the relapsed tumor proved evidence of an in vivo change of differentiation from predominantly papillary cystadenocarcinoma to carcinosarcoma.
  • The differentiation phenotype of OV-MZ-22 cells is that of smooth-muscle cells.
  • CONCLUSION: The change of histologic differentiation was apparently due to a selection process caused by platinum-containing chemotherapy.
  • [MeSH-major] Carcinosarcoma / pathology. Ovarian Neoplasms / pathology. Tumor Cells, Cultured
  • [MeSH-minor] Actins / biosynthesis. Animals. Cell Differentiation. Cystadenocarcinoma, Papillary / genetics. Cystadenocarcinoma, Papillary / metabolism. Cystadenocarcinoma, Papillary / pathology. DNA, Neoplasm / analysis. DNA, Neoplasm / genetics. Female. Humans. Intermediate Filament Proteins / biosynthesis. Karyotyping. Keratins / biosynthesis. Mice. Mice, Nude. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Transplantation


22. Li Y, Cui H, Chang XH, Feng J, Fu TY, Feng YJ, Wei LH: [Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice]. Ai Zheng; 2004 Feb;23(2):160-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment and comparison of two intraperitoneally transplanted human ovarian carcinoma models with immune reconstitution in severe combined immunodeficient mice].
  • BACKGROUND & OBJECTIVE: Ovarian carcinoma is leading cause of death in gynecologic malignancies.
  • The survival rate cannot be improved after routine surgery, chemotherapy, and radiotherapy.
  • Therefore biotherapy becomes the fourth treatment pattern for ovarian carcinoma.
  • Adequate experimental models for the development of biologic therapeutic strategies are needed.
  • Our purpose was to establish and compare two intraperitoneally transplanted human ovarian carcinoma models with human immune reconstitution in severe combined immunodeficient (SCID) mice.
  • METHODS: Six and ten C.B17/SCID mice were intraperitoneally injected with human ovarian adenocarcinoma SKOV3 and SKOV3.ip1 cells, respectively.
  • The latent periods of tumor growth were 20-41 days and 22-30 days, respectively (P >0.05).
  • While the mean survival time were 50-78 days and 32-43 days, respectively (P< 0.0001).
  • 83.3% (5/6) of the mice injected with ascites of the mice in SKOV3.ip1 group successfully formed new tumor mass and ascites.
  • Histological results showed the tumors of the two groups remained the characteristics of serous papillary adenocarcinoma of human ovary, and immunohistochemistry staining showed the ovarian associated antigen OC166-9 were both positive.
  • CONCLUSION: The two intraperitoneally transplanted human ovarian carcinoma models had been established in human PBL reconstituted SCID mice.
  • The SKOV3.ip1 model may be an ideal animal model for biotherapy research of ovarian carcinoma as it simulates the intraperitoneally disseminating behavior of human ovarian carcinoma in the patients with immune function, and it took relatively shorter time to be established.
  • [MeSH-major] Disease Models, Animal. Ovarian Neoplasms / immunology
  • [MeSH-minor] Animals. Female. Humans. Immunoglobulin G / blood. Immunohistochemistry. Mice. Mice, SCID. Neoplasm Transplantation. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14960235.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin G
  •  go-up   go-down


23. Markaki S, Protopapas A, Milingos S, Lazaris D, Antsaklis A, Michalas S: Primary malignant mesothelioma of the peritoneum: a clinical and immunohistochemical study. Gynecol Oncol; 2005 Mar;96(3):860-4
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential diagnosis between this rare tumor and both serous papillary carcinoma of the peritoneum and ovary can be problematic.
  • CASE: A 54-year-old woman presented to our institution with a 4-month history of dull epigastric pain and increased abdominal girth.
  • Exploratory laparotomy revealed the presence of extensive intraperitoneal dissemination of a malignant neoplasm without a recognizable primary site.
  • This was confirmed with a panel of immunohistochemical markers.
  • The patient despite having a complete response after adjuvant chemotherapy died 18 months after primary surgery.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15721439.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Shibahara K, Endo K, Ikeda T, Sakata H, Sadanaga N, Morita M, Kakeji Y, Maehara Y: Colon metastasis 20 years after the removal of ovarian cancer: Report of a case. Surg Today; 2009;39(2):153-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colon metastasis 20 years after the removal of ovarian cancer: Report of a case.
  • This report describes the case of a patient who had undergone surgery to resect bilateral ovarian tumors and then presented with colon metastasis 20 years later.
  • She had been operated on for bilateral ovarian cancer in 1987 and was treated by postoperative adjuvant chemotherapy.
  • The patient's follow-up showed no abnormality until 2006.
  • A right hemicolectomy with a partial resection of the ileum and a lymphadenectomy was performed.
  • Immunohistochemical staining during the pathological diagnosis showed the lesion to be colon metastasis from a serous papillary adenocarcinoma of the ovary.
  • The use of immunohistochemistry demonstrated the tumor to be of ovarian origin.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / secondary. Ovarian Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Colonoscopy. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Jul;22(7):805-15 [9669343.001]
  • [Cites] Surg Today. 2002;32(8):750-2 [12181732.001]
  • [Cites] Mod Pathol. 1996 Nov;9(11):1040-4 [8933513.001]
  • [Cites] Acta Chir Belg. 1990 Jul-Aug;90(4):166-71 [2239034.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):107-16 [10776968.001]
  • [Cites] Jpn J Surg. 1986 Sep;16(5):305-10 [3467109.001]
  • [Cites] Ann Pathol. 1999 Dec;19(6):492-8 [10617806.001]
  • (PMID = 19198996.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Ramalingam P, Middleton LP, Tamboli P, Troncoso P, Silva EG, Ayala AG: Invasive micropapillary carcinoma of the breast metastatic to the urinary bladder and endometrium: diagnostic pitfalls and review of the literature of tumors with micropapillary features. Ann Diagn Pathol; 2003 Apr;7(2):112-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Carcinomas with micropapillary features have been described in the breast, urinary bladder, lung, and ovary.
  • Unequivocal vascular invasion is usually present at the periphery of the tumor.
  • We present a case of a 59-year-old woman with a history of bilateral breast carcinoma status post-bilateral mastectomy, chemotherapy, and tamoxifen therapy.
  • Anderson Cancer Center (Houston, TX) for further treatment recommendations.
  • The mastectomy specimen showed an invasive ductal carcinoma with a significant micropapillary component.
  • The tumor cells from the breast, endometrium, and urinary bladder were positive for cytokeratin (CK) 7 and estrogen receptor and negative for CK20.
  • In view of the morphologic and immunohistochemical profile, the carcinoma in the endometrium and urinary bladder were interpreted as metastatic lesions from the breast primary.
  • Carcinomas with a micropapillary component are morphologically identical in the breast, urinary bladder, and lung.
  • However, micropapillary serous carcinoma has a different appearance more akin to borderline tumors of the ovary.
  • It is important to exclude metastatic carcinomas with micropapillary features before making a definite diagnosis of a primary tumor.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Papillary / secondary. Endometrial Neoplasms / secondary. Urinary Bladder Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Elsevier Inc. All rights reserved.
  • (PMID = 12715337.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / Receptors, Estrogen; 68238-35-7 / Keratins
  •  go-up   go-down


26. Lee KR, Nucci MR: Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis. Int J Gynecol Pathol; 2003 Jan;22(1):42-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian mucinous and mixed epithelial carcinomas of mullerian (endocervical-like) type: a clinicopathologic analysis of four cases of an uncommon variant associated with endometriosis.
  • The epithelial cells of ovarian mucinous carcinomas may sometimes appear similar to those of gastrointestinal or endocervical mucinous carcinomas, but most are composed of cells that do not suggest any particular derivation.
  • We report four cases of mucinous ovarian carcinoma in which the cells were entirely or almost entirely endocervical-like.
  • Two patients had bilateral tumors confined to the ovaries at initial staging; both also had synchronous endometrial carcinomas of the mucinous type.
  • In one of the latter cases a mullerian (endocervical-like) mucinous borderline tumor (MMBT) of the opposite ovary had been removed 5 years earlier, and in this case and two other cases the ovarian carcinomas had foci resembling MMBT, suggesting that they may be an invasive counterpart to these tumors.
  • The six tumors ranged from 4 to 19 cm; five were grossly cystic with papillary or solid areas, and one was entirely solid.
  • One tumor had a focally infiltrative growth pattern with a desmoplastic stromal reaction; the remaining five tumors had an exclusively confluent (expansile) pattern of invasion.
  • Endometriosis was present in residual ovarian tissue adjacent to four tumors in three patients and had marked epithelial proliferation in three.
  • All patients were treated postoperatively with chemotherapy and were without clinical recurrence with follow-up intervals of 8 months, 1.2 years, 2.9 years, and 3.8 years.
  • By immunohistochemical analysis the neoplastic epithelium was positive for estrogen and progesterone receptor proteins, vimentin, and cytokeratin 7, and negative or only focally positive for carcinoembryonic antigen and cytokeratin 20, a profile that differs from that of the usual mucinous ovarian carcinoma and is supportive of a mullerian derivation.
  • To better understand their clinicopathologic features and pathogenesis, this uncommon variant should be separated from the usual type in future studies of mucinous carcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometriosis / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12496697.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


27. Fukunaga M, Fujiwara Y, Naito Z: Hepatoid carcinoma with serous component of the fallopian tube: a case report with immunohistochemical and ultrastructural studies. Int J Gynecol Pathol; 2006 Jul;25(3):233-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was composed of hepatoid carcinoma (90%) and serous carcinoma (10%) components.
  • The hepatoid carcinoma was histologically characterized by a proliferation of round to polygonal cells arranged in a trabecular, tubular, sinusoidal, papillary, or solid pattern.
  • Both components showed an infiltration into the surface of the left ovary, omentum, peritoneum including the pouch of the Douglas, and serosa of the colon.
  • Ultrastructurally, the cytoplasm contained abundant ribosomes, moderate amounts of mitochondria, and rough endoplasmic reticulum that developed into a meshwork and contained mitochondria within it.
  • The patient received chemotherapy and was alive without disease at 10 months after surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810059.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins; 68238-35-7 / Keratins
  •  go-up   go-down






Advertisement